Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a Safety and Efficacy Study of β-globin Restored Autologous Hematopoietic Stem Cells for β-thalassemia Major Patients With CVS-654 Mutation

NCT04205435 is registered in ClinicalTrials.gov with Bioray Laboratories as lead sponsor.

NCT NCT04205435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a Safety and Efficacy Study of β-globin Restored Autologous Hematopoietic Stem Cells for β-thalassemia Major Patients With CVS-654 Mutation
Lead sponsor
Bioray Laboratories
Phase
Phase 1/2
Overall status
Terminated
Start date
November 1, 2021
Completion date
July 25, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

β-thalassemia major